It has been reported that hyperlipidemia increases lipotoxic cholesterol and saturated fatty acids (57); the levels of all fatty acids, especially palmitic acid (PA), are increased in the plasma of patients with CKD (58); and saturated fatty acids, including PA, undergo intracellular crystallization and activate NLRP3 (59). This evidence concerns the gene NLRP3 and chronic kidney disease.